Advancing Multiple Generations of Drug Candidates

Our strategy is to deliver on well-characterized psychedelic candidates and next generation candidates with enhanced drug profiles.

Pipeline concepts and opportunities for Classic Psychedelics, 2nd Generation / Optimized and 3rd Generation / NCES
1. Gasser 2014; J. Nerv. Ment. Dis.; 202(7).
IP: intellectual property; DMT: N,N-dimethyltryptamine; MDMA: 3,4-methylenedioxymethamphetamine; NCE: new chemical entity; PD: pharmacodynamics; PK: pharmacokinetics
×

Thanks for visiting!

You are leaving MindMed and will be automatically redirected to ${url} in a moment.

Change your mind?

Return to Mindmed